search button

Prevalence of K-Ras mutations in hepatocellular carcinoma: A A Turkish Oncology Group pilot study

  • Authors:
    • Nazım Serdar Turhal
    • Berna Savaş
    • Öznur Çoşkun
    • Emine Baş
    • Bülent Karabulut
    • Deniz Nart
    • Taner Korkmaz
    • Dilek Yavuzer
    • Gökhan Demir
    • Gülen Doğusoy
    • Mehmet Artaç

  • View Affiliations

  • Published online on: August 31, 2015     https://doi.org/10.3892/mco.2015.633
  • Pages: 1275-1279
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is the fifth most common male-predominant type of cancer worldwide. There is no effective treatment regimen available for advanced‑stage disease and chemotherapy is generally ineffective in these patients. The number of studies on the prevalence of K‑Ras mutations in HCC patients is currently limited. A total of 58 patients from 6 comprehensive cancer centers in 4 metropolitan cities of Turkey were enrolled in this study. Each center committed to enroll approximately 10 random patients whose formalin‑fixed paraffin‑embedded tumor tissues were available for K‑Ras, exon 2 genotyping. Two methods were applied based on the availability of adequate amounts of tumor DNA. In the first method, the samples were processed using TheraScreen. The genomic DNA was further used to detect the 7 most frequent somatic mutations (35G>A; 35G>C; 35G>T; 34G>A; 34G>C; 34G>T and 38G>A) in codons 12 and 13 in exon 2 of the K‑Ras oncogene by quantitative polymerase chain reaction (PCR). In the second method, the genomic DNA was amplified by PCR using primers specific for K‑Ras exon 2 with the GML SeqFinder Sequencing System's KRAS kit. The identified DNA sequence alterations were confirmed by sequencing both DNA strands in two independent experiments with forward and reverse primers. A total of 40 samples had adequate tumor tissue for the mutation analysis. A total of 33 (82.5%) of the investigated samples harbored no mutations in exon 2. All the mutations were identified via a direct sequencing technique, whereas none were identified by TheraScreen. In conclusion, in our patients, HCC exhibited a remarkably low (<20%) K‑Ras mutation rate. Patients harboring K‑Ras wild‑type tumors may be good candidates for treatment with epidermal growth factor inhibitors, such as cetuximab.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 3 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Turhal NS, Savaş B, Çoşkun Ö, Baş E, Karabulut B, Nart D, Korkmaz T, Yavuzer D, Demir G, Doğusoy G, Doğusoy G, et al: Prevalence of K-Ras mutations in hepatocellular carcinoma: A A Turkish Oncology Group pilot study. Mol Clin Oncol 3: 1275-1279, 2015.
APA
Turhal, N.S., Savaş, B., Çoşkun, Ö., Baş, E., Karabulut, B., Nart, D. ... Artaç, M. (2015). Prevalence of K-Ras mutations in hepatocellular carcinoma: A A Turkish Oncology Group pilot study. Molecular and Clinical Oncology, 3, 1275-1279. https://doi.org/10.3892/mco.2015.633
MLA
Turhal, N. S., Savaş, B., Çoşkun, Ö., Baş, E., Karabulut, B., Nart, D., Korkmaz, T., Yavuzer, D., Demir, G., Doğusoy, G., Artaç, M."Prevalence of K-Ras mutations in hepatocellular carcinoma: A A Turkish Oncology Group pilot study". Molecular and Clinical Oncology 3.6 (2015): 1275-1279.
Chicago
Turhal, N. S., Savaş, B., Çoşkun, Ö., Baş, E., Karabulut, B., Nart, D., Korkmaz, T., Yavuzer, D., Demir, G., Doğusoy, G., Artaç, M."Prevalence of K-Ras mutations in hepatocellular carcinoma: A A Turkish Oncology Group pilot study". Molecular and Clinical Oncology 3, no. 6 (2015): 1275-1279. https://doi.org/10.3892/mco.2015.633